COMP <GO>
LLY vs AMGN // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Eli Lilly and Company (NYSE) VS. Amgen Inc. (NASDAQ) • 15-METRIC TALLY: LLY 8
— AMGN 6
■ METRIC PARITY
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
options-implied-move
6.77%
LAST: $466.01 (+1.15%) • MKT CAP: $249.09B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LLY VS. AMGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LLY | AMGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.64% | 67.20% | +16.44 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 32.36% | 14.50% | +17.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 36.4x | 27.2x | +9.22 | AMGN | /valuation <GO> |
| Free Cash Flow Yield | 2.30% | 3.25% | -0.95 | AMGN | /fcf-yield <GO> |
| Operating Margin | 40.21% | 24.70% | +15.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | 31.90% | 21.00% | +10.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 45.51% | 10.00% | +35.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.49% | 2.06% | -1.57 | AMGN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.29 | 3.83 | +5.46 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.77% | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.6 | 67.0 | -0.40 | AMGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.51 | 0.87 | -0.36 | AMGN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.6x | 30.0x | +0.62 | AMGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.29T | $249.09B | $1.04T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LLY REV | AMGN REV | LLY GROSS % | AMGN GROSS % | LLY FCF | AMGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $65.18B | $36.75B | 83.0% | 67.2% | $16.81B | $8.10B |
| FY 2024 | $45.04B | $33.42B | 81.3% | 61.5% | $8.82B | $10.39B |
| FY 2023 | $34.12B | $28.19B | 79.3% | — | $4.24B | $7.20B |
| FY 2022 | $28.54B | — | 76.8% | — | $7.59B | — |
| FY 2021 | $28.32B | — | 74.2% | — | $7.37B | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LLY // BETA 0.51
AMGN // BETA 0.87